News
- Author:
- Andrew D. Bowser
Publish date: November 19, 2019
BOSTON – Hot topics included HBV natural history, novel therapies, and prevention.
News
- Author:
- Andrew D. Bowser
Publish date: November 18, 2019
Longer-than-expected survival times and substantial platinum sensitivity among women in the trial could have diluted an independent surgical effect...
News
- Author:
- Andrew D. Bowser
Publish date: November 16, 2019
BOSTON – PPAR agonist now warrants consideration as first-line treatment for “vexing” clinical issue.
News
- Author:
- Andrew D. Bowser
Publish date: November 14, 2019
BOSTON – Manageable hepatic adverse events for combination, now under evaluation in a phase 3 trial and accepted for priority review by the FDA.
News
- Author:
- Andrew D. Bowser
Publish date: November 12, 2019
BOSTON – NASHmap could serve as screening tool to reveal more potential undiagnosed patients, according to investigat...
News
- Author:
- Andrew D. Bowser
Publish date: November 12, 2019
BOSTON – Reduced mortality in HCC patients with complete response apparently driven by achievement of sustained virol...
News
- Author:
- Andrew D. Bowser
Publish date: November 12, 2019
BOSTON – While curing infection post transplant works, prevention would be preferable, investigators say.
News
- Author:
- Andrew D. Bowser
Publish date: November 12, 2019
NEW ORLEANS – Findings were similar to overall results of KRONOS, suggesting exacerbation history did not drive ...
News
- Author:
- Andrew D. Bowser
Publish date: November 11, 2019
There were no cardiovascular-related deaths and one event in treated patients who were followed for 20 years.
News
- Author:
- Andrew D. Bowser
Publish date: November 10, 2019
NEW ORLEANS – Outcomes with the combination therapy compared well with tiotropium monotherapy in patients not receiving inhaled corticosteroids
News
- Author:
- Andrew D. Bowser
Publish date: November 8, 2019
BOSTON – Durable response linked to less need for early renal replacement therapy, investigators say
News
- Author:
- Andrew D. Bowser
Publish date: November 8, 2019
BOSTON – Improvements in HbA1c and NASH biomarker favored the procedure over sham procedure in first-ever randomized, double-blind prosp...
News
- Author:
- Andrew D. Bowser
Publish date: November 8, 2019
BOSTON – Mild pruritus, minor decreases in LDL cholesterol are notable adverse effects of treatment, similar to others in class.
News
- Author:
- Andrew D. Bowser
Publish date: November 8, 2019
BOSTON – First-ever randomized study does suggest changes in peak HCV RNA and an HCV RNA change after infection.
News
- Author:
- Andrew D. Bowser
Publish date: November 8, 2019
BOSTON – Pangenotypic regimen may further progress toward elimination of hepatitis C, investigators say.
